|Articles|December 8, 2014
Sandoz's Biosimilar Shows Similarity to Amgen's Neupogen
Author(s)Agnes Shanley
Sandoz announces their version of filgrastim, a follow-on biologic for the treatment of neutropenia, is as safe and effective as Amgen's Neupogen.
Advertisement
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Ask the Expert: Commenting on Draft Regulations
2
SK pharmteco Invests in California Site to Overcome Peptide Purification Bottlenecks
3
Challenges, Innovations, and Future Outlook of Biologics Formulations
4
Global Study Confirms Survival Advantage of Mogamulizumab in Advanced Mycosis Fungoides and Sézary Syndrome
5
